Long-term outcome of imatinib 400 mg compared to imatinib 600 mg or imatinib 400 mg daily in combination with cytarabine or pegylated interferon alpha 2a for chronic myeloid leukaemia: results from the French SPIRIT phase III randomised trial
Author:
Guilhot FrancoisORCID, Rigal-Huguet Françoise, Guilhot Joëlle, Guerci-Bresler Agnès-Paule, Maloisel Frédéric, Rea Delphine, Coiteux Valérie, Gardembas Martine, Berthou Christian, Vekhoff Anne, Jourdan Eric, Berger Marc, Fouillard Loïc, Alexis Magda, Legros Laurence, Rousselot Philippe, Delmer AlainORCID, Lenain Pascal, Escoffre Barbe Martine, Gyan EmmanuelORCID, Bulabois Claude-Eric, Dubruille Viviane, Joly BertrandORCID, Pollet Bertrand, Cony-Makhoul Pascale, Johnson-Ansah Hyacinthe, Mercier Melanie, Caillot Denis, Charbonnier Aude, Kiladjian Jean-Jacques, Chapiro Jacques, Penot Amélie, Dorvaux Véronique, Vaida Iona, Santagostino Alberto, Roy Lydia, Zerazhi Hacene, Deconinck EricORCID, Maisonneuve Herve, Plantier Isabelle, Lebon Delphine, Arkam Yazid, Cambier Nathalie, Ghomari Kamel, Miclea Jean-Michel, Glaisner Sylvie, Cayuela Jean-Michel, Chomel Jean-ClaudeORCID, Muller Marc, Lhermitte LudovicORCID, Delord MarcORCID, Preudhomme Claude, Etienne Gabriel, Mahon François-Xavier, Nicolini Franck- Emmanuel, Guilhot Francois, Rigal-Huguet Francoise, Guilhot Joëlle, Guerci-Bresler Agnès-Paule, Rea Delphine, Coiteux Valérie, Gardembas Martine, Vekhoff Anne, Berger Marc, Legros Laurence, Rousselot Philippe, Lenain Pascal, Escoffre Barbe Martine, Dubruille Viviane, Cony-Makhoul Pascale, Johnson-Ansah Hyacinthe, Mercier Melanie, Aude Charbonnier, Roy Lydia, Cambier Nathalie, Cayuela Jean-Michel, Chomel Jean-Claude, Delord Marc, Preudhomme Claude, Etienne Gabriel, Mahon François-Xavier, Nicolini Franck-Emmanuel,
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Cancer Research,Hematology
Reference35 articles.
1. O’Brien S, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348:994–1004. 2. Druker BJ, Guilhot F, O’Brien SG, Gathmann I, Kantarjian H, Gattermann N, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–17. 3. Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, O’brien SG. High rates of durable response are achieved with Imatinib after treatment with interferon alpha plus cytarabine: results from the international randomized study of interferon and STI571 (IRIS) trial. Haematologica. 2009;94:1669–75. 4. Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376:917–27. 5. Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319–25.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
|
|